Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort

類似資料

• Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort
  著者:: T. Eigentler, 等
  出版事項: (2026-01-01)
• Abscopal effect of intratumoral therapy with daromun in locally advanced and lymphogenically metastasised malignant melanoma
  著者:: J. Schulte, 等
  出版事項: (2026-01-01)
• Efficacy and safety of daromun as neoadjuvant intralesional immunotherapy in locally advanced, resectable melanoma: experiences from a compassionate use program
  著者:: C. Straub, 等
  出版事項: (2026-01-01)
• Line-field confocal optical coherence tomography for monitoring intralesional immunotherapy with L19IL2/L19TNF (daromun) in recurrent basal cell carcinoma
  著者:: M.F. Vera Morandini, 等
  出版事項: (2026-01-01)
• CDA deficiency is not associated with higher sensitivity to immune checkpoint inhibitors in melanoma patients
  著者:: C. Gaudy-Marqueste, 等
  出版事項: (2024-12-01)